Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRITON2: Rucaparib in mCRPC with HRD
NCT02952534Phase 2Completed
- Sponsor
- pharma&
- Start
- Feb 2017
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 2, open-label, single-arm trial of rucaparib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by pharma&. Primary endpoint: Confirmed Objective Response Rate by Independent Radiology Review up to 3 years. Started Feb 2017; status: completed.
02
Drugs
rucaparib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02952534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02952534.